(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Terapia génica del cáncer > DA - CIMA - Terapia génica y Hepatología - Terapia génica del cáncer - Artículos de revista >

Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy
Autor(es) : Zabala, M. (Maider)
Alzuguren, P. (Pilar)
Benavides, C. (Carolina)
Crettaz, J. (Julien)
Gonzalez-Aseguinolaza, G. (Gloria)
Ortiz-de-Solorzano, C. (Carlos)
Gonzalez-Aparicio, M. (Manuela)
Kramer, M.G. (María Gabriela)
Prieto, J. (Jesús)
Hernandez-Alcoceba, R. (Rubén)
Palabras clave : Colorectal Neoplasms
Liver Neoplasms
Luminescence
Fecha incorporación: 2009
Editorial : BioMed Central
Cita: Zabala, M; Alzuguren, P; Benavides, C; Crettaz, J; Gonzalez-Aseguinolaza, G; Ortiz-de-Solorzano, C; Gonzalez-Aparicio, M; Kramer, MG; Prieto, J; Hernandez-Alcoceba, R. "Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy". Molecular Cancer 2009; 8 (2)
Resumen
BACKGROUND: Bioluminescent imaging (BLI) is based on the detection of light emitted by living cells expressing a luciferase gene. Stable transfection of luciferase in cancer cells and their inoculation into permissive animals allows the noninvasive monitorization of tumor progression inside internal organs. We have applied this technology for the development of a murine model of colorectal cancer involving the liver, with the aim of improving the pre-clinical evaluation of new anticancer therapies. RESULTS: A murine colon cancer cell line stably transfected with the luciferase gene (MC38Luc1) retains tumorigenicity in immunocompetent C57BL/6 animals. Intrahepatic inoculation of MC38Luc1 causes progressive liver infiltration that can be monitored by BLI. Compared with ultrasonography (US), BLI is more sensitive, but accurate estimation of tumor mass is impaired in advanced stages. We applied BLI to evaluate the efficacy of an immunogene therapy approach based on the liver-specific expression of the proinflammatory cytokine interleukin-12 (IL-12). Individualized quantification of light emission was able to determine the extent and duration of antitumor responses and to predict long-term disease-free survival. CONCLUSION: We show that BLI is a rapid, convenient and safe technique for the individual monitorization of tumor progression in the liver. Evaluation of experimental treatments with complex mechanisms of action such as immunotherapy is possible using this technology.
Enlace permanente: http://hdl.handle.net/10171/17178
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Terapia génica hepatitis virales - Artículos de revista
DA - CIMA - Oncología - Imagen del cáncer - Artículos de revista
DA - CIMA - Unidad de Imagen - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Terapia génica del cáncer - Artículos de revista

Ficheros en este registro:
Fichero:  MC38Luc1-pdf.pdf
Descripción: 
Tamaño:  762,17 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.